Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07206225) titled 'A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer' on Sept. 25.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Pfizer
Condition:
Non-muscle Invasive Bladder Cancer
Intervention:
Drug: PF-08052667
Drug: Sasanlimab
Drug: BCG
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: October 20, 2025
Target Sample Size: 294
Countries of Recruitment:
United States
France
Israel
Italy
South Korea
Spain
United Kingdom
France
Israel
I...